Johnson & Johnson has launched a late-stage trial for its second COVID-19 vaccine, a report said Monday.

The New Jersey-based drugmaker had already been conducting a stage-three trial for a vaccine that is administered in a single dose. This new late-stage trial is for a second Johnson & Johnson vaccine that involves two doses, according to the website BioPharma-Reporter.

The new trial will try to determine how effective the second dose may be in extending immunity, the site said.

Testing on J&J’s single-dose vaccine began in September and involves 60,000 people from the US, Mexico, South Africa and several countries in South America.

The newly launched two-dose immunization trial has 30,000 participants from countries including the US, Britain, France, Germany, Spain and the Philippines.

The news comes as a second coronavirus vaccine has shown remarkable results from its stage-three trial.

That vaccine, developed by Moderna, appears to be nearly 95 percent effective based on test results, the company announced Monday.

Last week, Pfizer and BioNTech said their vaccine seems to be at least 90 percent effective in fighting off the contagion.